Fablyn Articles
Ligand in deal with Chiva for global rights to Fablyn
12 October 2011
Pfizer/Ligand’s lasofoxifene reduces breast cancer risk in postmenopausal osteoporotic women
8 November 2010
Showing 1-2 of 2 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
